HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chattem

This article was originally published in The Rose Sheet

Executive Summary

Selsun Blue domestic sales rose 38% in first quarter (ended Feb. 28) versus the same period last year, when the brand was marketed by former owner Abbott Labs, Chattanooga, Tenn. firm reports during March 21 analysts call. Chattem, which bought Selsun Blue in March of 2002, renewed ad support for the brand in June (1"The Rose Sheet" April 15, 2002, p. 9). Double-digit growth for Gold Bond and pHisoderm in Q1 was achieved on the launch of new products. The performance of all three brands helped spur a 20.7% increase in Chattem's net revenues to $58.4 mil. in Q1, while net income reached $4.6 mil., compared to a $6.5 mil. loss last year. Chattem also announced it acquired certain international trademarks for the pHisoderm brand from GlaxoSmithKline in an effort to expand its pHisoderm business globally...

You may also be interested in...



Chattem Advertising Strategy Relies On “Guerrilla” Tactics – CEO Guerry

Chattem's advertising strategy focuses on acquiring media time "as a guerilla buyer as opposed to a big buyer," CEO Zan Guerry maintained at a Banc of America Securities consumer conference in New York April 8-10

DevaCurl Faces Multiple Class Actions As Latest Brand Linked To Hair Loss

The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.

Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.

UsernamePublicRestriction

Register

RS011065

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel